Abstract 66P
Background
Glioblastoma is the most common primary malignancy of the brain, affecting approximately 3 per 100 000 people, with a median overall survival of 15 months. Tumor-associated macrophages comprise up to 30% of the glioblastoma tumor microenvironment (TME) and consist of microglia and monocyte-derived macrophages (MDM). MDM arise from granulocyte-monocyte progenitors (GMP) or monocyte-dendritic cell progenitors (MDP). Our recent work identified a unique macrophage population expressing myeloperoxidase (MPO) and other GMP-associated genes associated with long-term survival in glioblastoma patients. ScRNA-seq analysis suggests that MPO+ macrophages may arise from GMPs and are metabolically distinct from MPO- MDM. Interestingly, adoptive transfer of GMP- versus MDP-derived monocytes into glioma-bearing mice had opposing effects on tumor growth. GMP-lineages specifically delayed tumor growth—aligning with our correlative findings in patients. The role of metabolic changes on the anti-tumor function of MDM of distinct developmental lineages remains unknown. We hypothesize that metabolic differences between GMP- and MDP-derived MDM may shift nutrient partitioning within the TME.
Methods
Bulk RNA-seq of GMP- and MDP-MDM was performed. To functionally assess metabolic differences between GMP- and MDP-MDM, Seahorse XFe96 analysis as well as metabolite analysis of conditioned media will be performed.
Results
Bulk RNA-seq of GMP- and MDP-MDM showed differential expression of many metabolic pathways, notably, a downregulation of the pentose phosphate pathway and aerobic respiration in GMP-MDM compared to MDP-MDM. Furthermore, co-culturing GMP- or MDP-MDM with GL261 glioma cell line suggests GMP-MDM are more phagocytic towards tumor cells. We will perform Seahorse XFe96 analysis and metabolite analysis of the conditioned media from GMP-MDM vs. MDP-MDM to investigate the functional impact of metabolic differences further.
Conclusions
Understanding how metabolic differences of MDM derived from different lineages shift nutrient competition in the TME will lead to a better understanding of the roles of macrophages in the TME.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
125P - Combination of navitoclax with alpelisib and trametinib to synergistically impair cell viability in high-grade ovarian cancer
Presenter: Lisa Wozelka-Oltjan
Session: Cocktail & Poster Display session
Resources:
Abstract
126P - Effect of sequential antitumoral treatment with immune checkpoint blockade and tyrosine kinase inhibitors in hepatocellular carcinoma
Presenter: Vincenza Ciaramella
Session: Cocktail & Poster Display session
Resources:
Abstract
127P - Novel bone-targeting of activatable sirolimus for targeted therapy of bone-resident cancers
Presenter: Alistare Sadra
Session: Cocktail & Poster Display session
Resources:
Abstract
128P - Network medicine approach identifies small molecule drugs as immune checkpoint inhibitors repurposable for rectal cancer
Presenter: Faheem Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
129P - Repurposing existing therapies for adrenal cancer: Unlocking new possibilities
Presenter: Anupama Samantasinghar
Session: Cocktail & Poster Display session
Resources:
Abstract
130P - Restoration of the mutant p53 protein upon treatment with small molecule modulators
Presenter: Elvina Gilyazova
Session: Cocktail & Poster Display session
Resources:
Abstract
131P - Trop 2 and its overexpression in metastatic colorectal cancer patients (mCRCp): Biological, clinical and therapeutic implications
Presenter: Andrea Mancuso Petricca
Session: Cocktail & Poster Display session
Resources:
Abstract
132P - Novel small molecule modulators for activation of mutant tumor suppressor p53
Presenter: Damir Davletshin
Session: Cocktail & Poster Display session
Resources:
Abstract
133P - Cytotoxic efficacy of artificial vesicles obtained from CAR-T cells by ultrasonication
Presenter: Ekaterina Zmievskaya
Session: Cocktail & Poster Display session
Resources:
Abstract
134P - Doxorubicin and olaparib (OLA) synergism in high-grade serous ovarian (HGOC) and triple-negative breast cancer (TNBC) cell lines with olaparib-resistance
Presenter: Jose Alejandro Perez Fidalgo
Session: Cocktail & Poster Display session
Resources:
Abstract